Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B

详细信息    查看全文

• 作者：Mei Sun ; Guolei Tan ; Jinyun Song ; Jianfang Wang ; Xuping Wu ; ^{xuping_wu@yahoo.com" class="auth_mail" title="E-mail the corresponding author}
• 刊名：Clinics and Research in Hepatology and Gastroenterology
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：40
• 期：5
• 页码：590-596
• 全文大小：687 K

文摘

We investigated the efficacy of entecavir (ETV) monotherapy in 54 naïve patients and 27 lamivudine (LMV) and/or adefovir (ADV) experienced patients.

Methods

Eighty-one chronic hepatitis B patients with a viral load above 4 log 10 copies/ml and high levels of serum alanine aminotransferase were treated with ETV 0.5 mg daily. The viruses of patients were sequenced before ETV therapy and after every three months of ETV therapy.

Results

Eight LAM-experienced and ADV-experienced patients emerged mutations in the ETV treatment. In one of these experienced patients, the ETV-resistant mutations were detected during ETV treatment, with the virological and the biochemical breakthrough. Two LAM-experienced and ADV-naïve patients were detected mutation during 1–2 years ETV therapy. All three LAM-naïve and ADV-experienced patients were detected mutations in the ETV treatment. Five in fifty for LAM-naïve and ADV-naïve patients showed mutations in the ETV monotherapy.

Conclusions

ETV has a high genetic barrier to resistance and the efficacy in LAM-experienced and/or ADV-experienced patients were much lower than in naïve patients.